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Abstract
Background: The nature and extent of inflammation seen in multiple sclerosis (MS) varies throughout
the course of the disease. Changes seen in CD4þ T-helper cells in relapsing–remitting (RR) MS and
secondary progressive (SP) MS might differ qualitatively and/or quantitatively.
Objective: The objective of this paper is to study the frequencies of all major CD4þ T-helper subtypes
– Th17, Th22 and Th1 lineage cells – in relapse, remission and secondary progression alongside CCR6
status, a chemokine receptor involved in migration of these cells into the central nervous system.
Methods: We compared 100 patients (50 RRMS and 50 SPMS) and 50 healthy volunteers and per-
formed flow cytometric analysis of lymphocytes in blood samples.
Results: We demonstrated raised frequencies of various cell types along the Th17 axis; Th17, Th17.1
(IL-17þ interferon gammaþ) and dual IL-17þ IL-22þ cells in RRMS. Th22 and CCR6þ Th1 cells
(nonclassical Th1) were also increased in RRMS. All these cells were CCR6þ. Only Th17 frequencies
were elevated in SPMS.
Conclusions: Increased frequencies of Th17 cells are implicated both in RRMS and SPMS. The CCR6
pathway includes Th17, Th22 and Th1 nonclassical cells, of which Th22 and Th1 cells represent the
greatest subsets in MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune neurode-
generative disease thought to require myelin-
reactive CD4þ T-cells. They are believed to play a
dominant role in relapsing–remitting MS (RRMS) in
which focal white-matter inflammatory lesions are
observed, whereas their role is less clear in second-
ary progressive MS (SPMS), characterised by path-
ological changes occurring mainly outside focal
inflammatory lesions. Though MS is an organ-
specific disease, reduction in inflammatory exacer-
bations caused by the blockage of the T-cell influx
into the central nervous system (CNS) with disease-
modifying treatments (DMTs) highlights the role of
peripheral immunity.
The myelin-reactive CD4þ cells most commonly
implicated in MS are of Th1 and Th17 lineage,
defined on the basis of production of interferon
gamma (IFNc) and interleukin 17 (IL-17), respec-
tively. Most studies have not demonstrated any dif-
ference in peripheral frequency of Th1 cells in MS.
Th17 are a much smaller proportion of CD4þ cells
(1%–3%) but their pathogenic potential surpasses
their absolute numbers.1 Literature has clearly dem-
onstrated that Th17 cells are intrinsically unstable
and functionally heterogeneous, consisting of subpo-
pulations that differentially produce IL-17, alone or
in combination with other proinflammatory cyto-
kines, and thereby have various phenotypes.
Double-positive IL-17þ IFNcþ cells, termed
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Th17.1; and double-positive IL17þ IL-22þ cells are
the most frequent ones. IL-22 is not only co-
expressed by Th17-lineage cells but also solely pro-
duced by Th22, a separate lineage implicated in
autoimmune diseases such as psoriasis, but is rela-
tively unexplored in MS.2 Nonclassical Th1, IFNc-
producing cells sharing some features with Th17,
have recently been shown to be increased in the
cerebrospinal fluid (CSF) of patients with MS as
well as other neurological conditions.3
In this study, we set out to look at all the major
T-helper cell subsets – Th17, Th17.1, other pheno-
types of IL-17 producers – Th22 and Th1 cells in
relapse, remission and secondary progression in MS
along with their CCR6 status, a chemokine receptor
involved in the influx of these cells into the CNS.
We demonstrate the presence of higher frequencies
of Th17 cells and other Th17-lineage multiple cell
phenotypes in RRMS but only of Th17 cells in
SPMS. Th22 cells were also increased in MS. All
the involved cells are CCR6þ and are of pathogenic
significance.
Patients and methods
Study Participants
The study was carried out with ethical approval in
accordance with the Declaration of Helsinki (ethics
reference: 11/WM/0206). Patients and healthy con-
trols were recruited from Royal Stoke MS Centre of
Excellence, University Hospital North Midlands,
United Kingdom. Laboratory work was performed
at the Centre for Translational Inflammation
Research, University of Birmingham and the
Institute of Science and Technology in Medicine,
Keele University.
A set of i) 100 patients (50 patients with RRMS) and
50 patients with SPMS, and ii) 50 healthy controls
were compared (Table 1). MS was diagnosed by
using the McDonald 2010 diagnostic criteria.4 The
subtypes RRMS and SPMS were defined as per clin-
ical phenotypes given by Lublin et al.5 in 2014; and
a minimum of one year of gradual worsening was
required to define SPMS.6 Healthy volunteers (HVs)
were recruited from patients’ spouses or partners,
and family members who had no history or clinical
evidence of neurological, systemic inflammatory or
autoimmune disease.
For the relapse group, patients were recruited at the
time of relapse (n¼ 26) at the first opportunity as
they presented to the relapse clinic. Relapse was
confirmed by objective evidence of neurological
deterioration with worsening of Expanded
Disability Status Scale score (EDSS) by at least
0.5. The remission group (n¼ 39) consisted of
RRMS patients who had been stable and had their
last clinical relapse at least six months previously.
Twenty out of 26 patients recruited at the time of
relapse were also recruited to the remission group.
Forty-three out of the 50 RR patients had at least one
relapse in the two years before the study period.
Most patients were treatment naive, and 15 out of
65 RRMS patients were on IFN beta (IFNb) treat-
ment; these were recruited at the time of relapse.
Sixteen out of the 50 SPMS patients recruited were
within the first four years of onset of the SP phase.
Five out of 50 SPMS patients had superimposed
relapses. We measured disease severity by EDSS.
Other data collected included smoking status and
treatment status: treatment naive vs on DMT.
Ambulation was measured by ambulation score, a
functional score of EDSS, and fatigue was measured
by Modified Fatigue Impact Score-21 (MFIS-21).
Sample preparation and flow cytometry
Blood samples were collected in EDTA tubes.
Samples collected were diluted with an equal
volume of RPMI-1640 (Sigma-Aldrich, Dorset,
UK) layered onto Ficoll-Paque Plus (GE
Healthcare Bioscience), and centrifuged at 400 g at
20C for 30 minutes. The peripheral blood mononu-
clear cell (PBMC) layer was removed and washed
three times in RPMI 1640 before counting. Freshly
isolated PBMCs were incubated stimulated with
phorbol myristate acetate (50 ng/ml), ionomycin
(750 ng/ml) and Brefeldin A (2 mg/ml) for three
hours at 37C (Sigma-Aldrich). Stimulated cells
were then stained for surface markers and intracel-
lular cytokine production. Antibodies specific for
surface markers were added for 20 minutes at 4C.
PBMCs were then fixed and permeabilised accord-
ing to the manufacturer’s instructions (FIX &
PERM, Life Technologies, UK) before staining
with antibodies specific to intracellular markers.
The antibodies used were anti-CD3, -CD4, -CCR7,
-CCR6 (all four BioLegend); -CD45RA (BD
Biosciences); and -IFNc, -IL-17A, -IL-22 (all three
eBioscience). Stained cells were resuspended in
phosphate-buffered saline and 2% bovine serum
albumin and were analysed using a multicolour
Dako-Cyan cytometer. Flow data were analysed
using Kaluza Flow Cytometry Analysis Software
(Beckman Coulter). Isotype control antibodies or
unstimulated controls (for cytokine analysis) were
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used to determine positivity and define the gating
strategy (Supplementary Figure 1).
Statistical analysis
Statistical analysis was performed using GraphPad
Prism 6 software. To analyse the differences in cell
frequencies, we used the Mann-Whitney test for
two-groups comparison and the Kruskal-Wallis test
for three-groups comparison. A p value of <0.05
was considered to be statistically significant
with descriptions as *p< 0.05, **p< 0.01 and
***p< 0.001.
Results
Th17 cells increased in RRMS and SPMS, whereas
Th17.1– dual IL-17 IFNc cells increased only in
RRMS
Th17 cells were defined as IL-17Aþ cells. Th17.1
cells were defined by dual expression of IL-17
and IFNc. Both Th17 and Th17.1 were CCR6þ
(Figure 1(a–d)).
Th17 cells increased in MS as compared to HVs
(median 0.55 and 0.35% of memory CD4þ cells.
respectively) (p¼ 0.0002) (Figure 1(e)). Th17
cells increased both in RRMS as compared to
HVs, as well as in SPMS as compared to HVs
(p¼ 0.0015) though the difference seen between
the RRMS and SPMS groups was not significant
(Figure 1(f)). Comparison of RRMS patients in
relapse or remission showed no significant differ-
ence in Th17 frequencies (Figure 1(g)). There was
no difference in Th17-cell frequencies in the
female vs male groups either in the MS or in HV
categories (data not shown). We also conducted a
subgroup analysis of RRMS patients with and
without any relapse in the last two years vs
SPMS and observed no difference. Similarly,
comparison of treatment-naive vs IFNb-treated
patients showed no difference in Th17-cell fre-
quencies (data not shown).
Th17.1, dual–IL-17þ IFNcþ cells increased in MS
as compared to HV (median 0.04 and 0.03, respec-
tively) (p¼ 0.030) (Figure 1(h)). Increased
Table 1. Demographics of study participants and basic clinical measures.
HCs MS SP RR REL REM
Patients, n 50 100 50 50 26 24
Sex, male, female n
(% of women)
22 M, 28 F
(56)
28 M, 72 F
(72)
13 M, 37 F
(74)
15 M, 35 F
(70)
11 M, 15 F
(57.6)
8 M, 16 F
(66.6)
Age median (range), y 49 (19–75) 49 (19–77) 56 (37–77) 45 (19–66) 45 (19–65) 45 (19–66)
Age at onset median
(range), y
NA 33 (17–52) 34 (17–52) 31(18–46) 31 (18–46) 31 (18–45)
Disease duration
median (range), y
NA 15 (1–52) 20 (5–52) 13 (1–32) 11 (1–31) 14 (1–32)
Smoking status
(S, Ex, NS)
13, 4, 33 20, 2, 56 9, 17, 24 11, 7, 32 6, 11, 9 7, 7, 10
Relapse in last
two years, n
NA 43 5 43 NA NA
DMT status NA 15/100a None 15/50 6/26 9/24
Disease severity
median (range),
EDSS
NA 6.5 (4.5–7.5) 3.0 (1.0–4.0) 6 (5.0–8.0)b 3.0 (1.0–4.0)
Ambulation Unrestricted Unrestricted
to WC
300 m to WC Unrestricted to
500m
100m with
bilateral support
to wheel chair bound
at time of relapse
Unrestricted
to 500m
Fatigue median (range),
measured by MFIS-21
NA 54 (4–84) 54 (14–84) 54 (4–84) 54 (18–84) 54 (4–84)
HC: healthy controls; DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; Ex: ex-smoker; F: female; M: male; MFIS:
Modified Fatigue Impact Score; MS: multiple sclerosis; NA: not available; NS: nonsmoker; REL: relapsing; REM: remitting; RR: relapsing–
remitting multiple sclerosis; S: smoker; SP: secondary progressive multiple sclerosis; WC: wheelchair.
aInterferon beta. bRelapse was confirmed by deterioration of EDSS by at least 0.5.
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frequencies were also seen in RRMS as compared to
HVs and in SPMS as compared to HVs (p¼ 0.049)
(Figure 1(i)). There was no significant difference
noted on comparison of relapse and remission
(Figure 1(j)), and in RRMS patients with or without
any relapse in the last two years.
Th22 and IL-22-secreting Th17 cells increased
in RRMS
We looked at solo IL-22 producers, and dual IL-22þ
IL-17Aþ cells (Figure 2(a)). Solo IL-22 producers,
called Th22 cells, are of separate T-cell lineage,
whereas dual–IL-17Aþ IL-22 secretors are consid-
ered to be of Th17 lineage. Both these cell popula-
tions express CCR6, as shown in Figures 2(b) and (c).
Th22s were significantly elevated in MS as com-
pared to HVs (median 1.35% and 0.95%, respec-
tively) as a percentage of memory CD4þ cells
(p¼ 0.0434) (Figure 2(d)). There was no statistically
significant difference observed on comparing the
RRMS, SPMS and HV groups (Figure 2(e)). There
was no significant difference observed in the relapse
vs remission phase (Figure 2(f)).
Figure 1. Th17 and Th17.1 cells in MS. (a) Representative data demonstrating IL-17Aþ and IFNcþ expression (gated on CD4þ memory cells).
Numbers represent the percentage of cells within the quadrant, with negative gates set based on unstimulated controls. (b) Data demonstrating
CCR6 expression on IL-17þ cells (gated on CD4þ memory cells). The histograms (Figures (c) and (d)) show CCR6 status of IL-17Aþ cells and
IL-17Aþ IFNcþ cells, respectively. Th17 as a proportion of CD4þ memory cells (e) in MS vs HV, (f) in RRMS vs SPMS and HV, and (g) in
relapse vs remission. Th17.1 as a proportion of CD4þ memory cells (h) in MS vs HV, (i) in RRMS vs SPMS and HV, and (j) in relapse vs
remission. Bars indicate the median value for each group. HV: healthy volunteers; IL-17A: interleukin 17A; IFNc: interferon gamma; MS:
multiple sclerosis; REL: relapse; REM: remission; RR: relapsing–remitting multiple sclerosis, SP: secondary progressive multiple sclerosis;
Th17: T-helper 17 cell. Mann-Whitney test was performed for comparison of cross data between HV and MS; and between REL and REM.
Kruskal-Wallis test was performed for the comparison between HV, RR and SP groups. Bars indicate median values (*p< 0.05, **p< 0.01,
***p< 0.001); all other comparisons were nonsignificant (p> 0.05).
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IL-22þ IL-17Aþ dual-expression cells also
increased in MS as compared to HV (median 0.07
and 0.12, respectively) (p¼ 0.0091) (Figure 2(g)),
more specifically in the RRMS group as compared
to the HVs (p¼ 0.033) but not as compared to the
SPMS group (Figure 2(h)). There was no significant
change in the relapse vs remission phase on cross-
sectional data (Figure 2(i)).
Although we showed both these cell types frequen-
cies are elevated in MS, we wanted to look for what
was the bigger source of IL-22, Th22 or dual
IL-17Aþ IL-22þ cells. As per our data, a median
of 1.35% of memory T cells were Th22 cells but
only 0.12% coexpressed the two cytokines in MS,
thus Th22 cells were a bigger source of IL-22 than
dual expressers (Table 2).
Nonclassical Th1 cells increased in RRMS
Th1s, defined as IFNc-secreting memory CD4þ T
cells, were analysed alongside their CCR6 status
(Figure 3).
Figure 2. Th22 and IL-17Aþ IL-22þ cells in MS. (a) Representative data demonstrating IL-17Aþ and IL-22þ expression (gated on
CD4þmemory cells). Numbers represent the percentage of cells within the quadrant, with negative gates set based on unstimulated controls. The
histograms (b and c) show CCR6 status of IL-22þ cells and IL-17Aþ IL-22þ cells, respectively. Th22 as a proportion of CD4þmemory cells (d)
in MS vs HV, (e) in RRMS vs SPMS and HV, and (f) in relapse vs remission. Dual IL-17Aþ IL-22þ cells as a proportion of CD4þmemory cells
(g) in MS vs HV, (h) in RRMS vs SPMS and HV, and (i) in relapse vs remission. Bars indicate the median value for each group. HV: healthy
volunteers; IL: interleukin; MS: multiple sclerosis; REL: relapse; REM: remission; RR: relapsing–remitting multiple sclerosis, SP: secondary
progressive multiple sclerosis; Th17: T-helper 17 cell. Mann-Whitney test was performed for comparison of cross data between HV and MS; and
between REL and REM. Kruskal-Wallis test was performed for the comparison between HV, RR and SP groups. Bars indicate median values
(*p< 0.05, **p< 0.01, ***p< 0.001); all other comparisons were nonsignificant (p> 0.05).
Kalra et al.
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Th1-cell frequencies were unaffected in MS as
compared to HV (Figure 3(d)). There was no
difference observed in comparing the RRMS, SPMS
and HV groups (Figure 3(e)). Th1s were not altered
between relapse and remission (Figure 3(f)). This was
in keeping with the previous literature.
Almost one-third of Th1s were classical, CCR6–
Th1 cells, with the remainder IFNcþ CCR6þ cells
defined as nonclassical Th1 cells (Figure 3(b and c)).
Nonclassical Th1 cells increased in MS as compared
to the HV group (p¼ 0.048) (Figure 3(g)). The
increased frequencies were also observed in RRMS
as compared to SPMS and HVs (p¼ 0.028) (Figure 3
(h)). The difference in relapse and remission phases
for nonclassical Th1-cell frequencies did not reach a
level of significance (Figure 3(i)). Nonclassical and
classical Th1 showed similar median fluorescence
intensity for IFNc, suggesting a similar degree of
IFNc expression (data not shown).
Nonclassical Th1 cells represented a median 2.2%
of the memory T-cell population. Thus, the non-
classical Th1 cell population formed a bigger pro-
portion of the memory T-cell population than Th22
and Th17, which represented 0.95% and 0.35%
of CD4þ T cells, respectively. Classical Th1 cells
constituted a median of 7.5% of memory T cells
(Table 2).
Discussion
Elevations in CD4þ Th17-cell frequencies in the
blood and CSF, with likely reduction in peripheral
blood frequency during relapses, are well reported in
RRMS.7–10 Treatment responsiveness to steroids and
IFNb is paralleled by a reduction in Th17 frequency
in the blood.8,11 Treatment with natalizumab, on the
other hand, showed an elevation in peripheral Th17
frequency because Th17 cells are locked out of the
CNS and other tissues.10 Segal alluded to increased
frequencies of Th17 cells in SPMS in a review based
on his previously unpublished data.12 There is little
evidence for changes in Th17 frequency in SPMS.
A histopathological study by Tzartos et al. in 2008
reported the presence of Th17 and IL-17 messenger
RNA in chronic lesions and normal-appearing white
matter, pointing to their role in SPMS also.13 Our
study is the first robust clinical evidence of increased
blood frequency of Th17 in SPMS.
Little is known about the clinical relevance and fre-
quency of various other cell phenotypes of Th17 lin-
eage inMS.We showed an elevation of Th17.1 inMS,
especially in RRMS. Th17.1 cells are Th1-like cells of
Th17 origin.1 A number of definitions of Th17.1 cells
are in use in the literature, based on the cytokine coex-
pression IL-17 with IFNc, like ours, and/or the pres-
ence of chemokines CCR6 and CXCR3 with or
without CCR4þ, and/or based on coexpression of
transcription factor T-bet, RORC.14,15 Th17.1 cells
are considered pathogenic in experimental autoim-
mune encephalomyelitis (EAE).16 Th17.1 cells may
be more pathogenic than Th17 cells in MS but there
are not enough data out to make definite conclusions
on their clinical importance and frequencies. Van
Langelaar and colleagues have shown that increased
frequencies of Th17.1 cells are associated with MS
Table 2. Relative proportion of cells as a percentage of CD4+memory cells in HV and MS. Numbers
represent median and range(in brackets). Mann-Whitney tests were performed for comparison of cross-
sectional data between HV and MS. Exact P-values are given.
Cell type (% of CD4+
memory cells) HV MS
Th17 0.35 (0 -1.50) 0.55 (0 -1.85)
p value-0.0002
Th17-IFN gamma 0.03 (0 – 0.19) 0.04 (0 – 0.24)
p value-0.0030
Th22 0.95 (0-3.93) 1.35 (0.48-10.84)
p value-0.0434
Th22-17 0.07 (0-0.51) 0.12 (0-0.60)
p value-0.0091
Th1 10.83 (0.08-29.70) 9.83 (0.06-31.62)
p value-0.5511
Non-classical Th1 2.20 (0-8.40) 2.21(0-9.48)
p value-0.0409
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onset, disease activity, the tendency to relapse and
early conversion from clinically isolated syndrome
to clinically definite MS.14
Dual-positive IL-17Aþ IL-22þ cells have a separate
pathogenic relevance to Th22 cells, another IL-22
producer. This is because the function of IL-22
depends on its coproduction with IL-17A, which
also regulates its expression.17 The presence or
absence of IL-17A governs the balance between
proinflammatory vs tissue-protective effects of
IL-22.17 We showed that Th22 cells were a bigger
source of IL-22 than dual expressers in MS. This is
in parallel to observations by Muls et al. in 2017.18
Th22 cells have been implicated in a number of
inflammatory and autoimmune conditions.19 Rolla
and colleagues reported that Th22 cells are elevated
in RRMS patients and express high levels of CCR6,
which confers a CNS-homing property but lower
levels of IFNAR1 as compared to Th17 cells, and
were therefore not sensitive to IFNb therapy,
unlike Th17, conferring treatment resistance.20
Figure 3. Th1 and nonclassical Th1 cells in MS. (a) Representative data demonstrating IL-17Aþ and IFNcþ expression (gated on CD4þmemory
cells). Numbers represent the percentage of cells within the quadrant, with negative gates set based on unstimulated controls. (b) Data demon-
strating CCR6 expression on IFNcþ cells (gated on CD4þmemory cells). (c) The histogram shows CCR6 status of IFNcþ cells. Th17, as
proportion of CD4þ memory cells, (d) in MS vs HV, (e) in RRMS vs SPMS and HV, and (f) in relapse vs remission. Nonclassical Th1 cells,
CCR6þ IFNcþ CD4þ cells, as a proportion of CD4þ IFNcþ cells (g) in MS vs HV, in RRMS vs (h) SPMS and HV, and (i) in relapse vs
remission. Bars indicate the median value for each group. Mann-Whitney test was performed for comparison of cross data between HV and MS;
and between REL and REM. Kruskal-Wallis test was performed for comparison between HV, RR and SP groups. Bars indicate median values
(*p< 0.05, **p< 0.01, ***p< 0.001); all other comparisons were nonsignificant (p> 0.05). HV: healthy volunteers; IL-17A: interleukin 17A;
IFNc: interferon gamma; MS: multiple sclerosis; REL: relapse; REM: remission; RR: relapsing–remitting multiple sclerosis, SP: secondary
progressive multiple sclerosis; Th17: T-helper 17 cell.
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All these CD4þ Th subsets express CCR6, which is
relevant for their influx into the CNS, with high
expression of CCL20, the ligand for CCR6, in the
choroid plexus.10,21
Our results show increases in the Th17 axis, both in
RRMS and SPMS, though the extent of involvement
is much less in SPMS. RRMS shows elevation in all
components of the Th17 axis, i.e. Th17, Th17.1,
IL-17þ IL-22þ dual-expression cells, but the
inflammation in SPMS is characterised by a rise in
Th17 cells only. This differential involvement of
immune cell subsets and mediators during RRMS
and SPMS holds important implications for the path-
ogenesis and therapeutics of these disease subtypes.
The cumulative evidence from various pathology
and imaging studies shows that the nature of
immune dysregulation evolves during the course of
MS with the presence of widespread microglial acti-
vation in macroscopically normal-appearing white
matter and lymphoid follicles in the leptomeninges
of SPMS.22,23 This, along with our data, suggests
that there is ongoing neuroinflammation in the path-
ogenic process, but perhaps via pathways that are
distinct from those dominant in the RR phase.
We also demonstrate that various cell frequencies
that were altered in MS belong to the CCR6 path-
way. Though the Th17-axis cells forms an important
part of the CCR6 pathway through Th17, Th17.1 and
IL-17þ IL-22 dual-expression cells, and is most
addressed, Th22 and nonclassical Th1 form an
even bigger proportion of this pathway.
Nonclassical Th1 cells also form the dominant
CCR6þ T-helper subset in CSF of MS patients as
well as other neurological conditions.3
Nonclassical Th1s are interesting cell subsets. Recent
literature has suggested that these cells are of Th17
origin, transitioning into Th1, thus ex-Th17.1,3 They
have an overlapping transcriptional profile with Th17
cells because they express RORC, alongside classical
Th1 markers like IFNG and TBX21, along with the
CXCR3 surface marker expression.1,3 More studies
are needed to understand their pathogenic potential.
The EAE model of MS demonstrates that Th17 and
Th1 both are encephalitogenic. Even though Th17
cells may be more potent inducers of myelin damage
than Th1, the jury is still out as to whether Th17 or a
high Th17 to Th1 ratio–driven EAE produces a dif-
ferent or severer phenotype of EAE than that of Th1.
Th17 and Th1 cells both are capable of causing spinal
cord inflammation and brainstem, cerebellar,
supraspinal inflammatory as well as optic nerve
inflammatory lesions with similar degrees of inflam-
mation, demyelination and axonal damage, and
regional predisposition with variable Th17 to Th1
ratio has not been proven.24–28 Studies in MS are
relatively fewer and have shown that RRMS with
predominant spinal cord lesions was mainly driven
by Th17 cells, whereas brain lesion–dominant MS
is associated with Th1 cells, possibly alongside their
counterpart innate lymphoid cells.29,30 It is also worth
highlighting that Th17 cells are not just restricted to
MS but are also involved in other T-cell–mediated
neuroinflammatory conditions including in neuroin-
flammation seen in traditional neurodegenerative dis-
eases such as Parkinson disease and Alzheimer
disease and their animal models.28 Th17 cells there
too are believed to contribute to chronic neuroinflam-
mation, perpetuating neurodegenerative processes.
We acknowledge that we have studied multiple cell
types and made multiple comparisons. We made
three comparisons (HV vs MS; HV vs RRMS and
SPMS; and relapse vs remission) for each of the cell
subtypes we studied (Th17, Th17.1, Th22, dual
IL22þ IL17þ cells; total Th1 and nonclassical
Th1 cells), and therefore, there is a chance of type
1 statistical error; however, all of the comparisons
made were a priori and hypothesis driven, and along
the Th17/Th1 cell axis. Also, for some measures,
e.g. Th17, frequencies were determined in more
than one analysis, which provides some reassurance
about the validity of these results.
Our study reports that the Th17-axis cell phenotypes
are increased in MS. We confirm and expand on
previous immunological findings seen along the
Th17 axis in RRMS but also make some novel
observations in SPMS. We show the relative contri-
butions various CCR6þ Th cells make toward the
inflammation in MS in this relatively large, robust
clinical study. Although our study alludes to the
involvement of Th17 cells in the secondary progres-
sion of MS, further studies are needed to study their
role in the progression and pathogenesis of MS.
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